KRYSTAL-10
30 Nov 2021
Trial Summary
Study 849-010 is an open-label, randomized Phase 3 clinical trial comparing the efficacy of MRTX849 administered in combination with cetuximab versus chemotherapy in the second-line treatment setting in patients with CRC with KRAS G12C mutation.
Acronym:
KRYSTAL 10
ACTRN/NCT /ethics:
NCT04793958
Scientific title:
A Randomized Phase 3 Study of MRTX849 in Combination With Cetuximab Versus Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation With Disease Progression On or After Standard First-Line Therapy
Sponsor / Cooperative group:
Mirati Therapeutics Inc
Trial & Patient Characteristics
| Cancer Type | Bowel and colon |
|---|---|
| Trial Type | Treatment |
| Phase | Phase III |
| Age Range | 18 years and older |
| Sex | All |
| Tumour Stream | Advanced Colorectal Cancer with KRAS G12C mutation |
| Cancer Stage | Locally Advanced, Metastatic or Widespread |
| Anticipated Start Date | 2021-03-15 |
| Anticipated End Date | 2023-09-30 |
Participating Hospitals
| Hospital | Flinders Medical Centre |
|---|---|
| Clinical Trial Coordinator | Hannah Adelson |
| Hannah.adelson@sa.gov.au | |
| Phone | 08 8206 4835 |
| Principal Investigator | Professor Chris Karapetis |
| Recruitment Status | Recruiting |